Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

AUPH

0.00

Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in risk]; p=0.0062) and worsening proteinuria (HR=0.22 [a 78% reduction in risk]; p<0.0001). 

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.